For CaHA materials intended for medical-device development and manufacturing, quality assessment often begins with batch test results: phase identity, Ca/P ratio, particle-size distribution, and impurity limits. These results matter, but they describe a batch after manufacturing is complete. Consistent supply also depends on whether the manufacturing process and measurement system remain under control. Raw material, formed microspheres, and a finished medical device are different material levels. The FDA examples below are used only to discuss particle-manufacturing changes within specific finished-device systems.
In 2026, the U.S. FDA published four PMA supplement records involving CaHA particle manufacturing for the RADIESSE product family. The changes concerned sieving, drying, dynamic crossflow filtration, and post-sterilization particle-size testing. The public pages do not disclose process parameters, validation data, or performance improvements. Their value is different: they show how apparently ordinary equipment and test-system changes remain part of a medical device's controlled lifecycle.
Four Public Records Cover Different Control Points
| Decision date | FDA record | Publicly described change |
|---|---|---|
| 2026-03-24 | P050052/S176 | Implementation of a new system named Green Sieve System for CaHA particles used in RADIESSE and RADIESSE (+) |
| 2026-03-24 | P050052/S177 | Implementation of a conical dryer in CaHA particle manufacturing for RADIESSE and RADIESSE (+) |
| 2026-05-14 | P050052/S178 | Installation and qualification of a new quality-laboratory microscope for post-sterilization particle-size testing of RADIESSE and COAPTITE |
| 2026-06-26 | P050052/S179 | Modification of the Dynamic Crossflow Filtration system used in CaHA particle manufacturing for RADIESSE, RADIESSE (+), and COAPTITE |
All four records were handled as 30-Day Notices. Under FDA requirements, qualifying modifications to manufacturing procedures or methods that affect device safety or effectiveness may be submitted through the 30-Day Notice pathway. If FDA finds a notice inadequate, it may be converted to a 135-day PMA supplement. Other types of design, site, performance, or quality-control changes may require different postapproval submissions depending on their nature. Equipment and process updates therefore cannot all be treated as the same type of submission.
Screening and Drying Shape the Particle Population
Screening controls a distribution, not an isolated average. Two batches may have similar D50 values while differing in D10, D90, distribution tails, and out-of-specification fractions. After a sieve-system change, the relevant question is whether the process continues to produce the intended particle population within its established window. Our article on why CaHA D50 and SEM observations may not match explains the measurement distinction in more detail.
Drying is also more than moisture removal. The transition from a wet to a dry state may influence agglomeration, interparticle bonding, and subsequent dispersion. S177 states only that a conical dryer was implemented in the manufacturing process. It provides no temperature, vacuum, rotation-speed, endpoint-moisture, or material-change data. The record supports treating the dryer as part of the controlled process; it does not support speculation about proprietary parameters or the magnitude of any product change.
Filtration and Measurement Require Different Controls
In particle processing, filtration may be used for solid-liquid separation, washing, particle recovery, or concentration. S179 does not identify the specific role of dynamic crossflow filtration in this process, nor does it state which impurity, ion, or particle attribute was affected. The defensible conclusion is narrower: the system forms part of CaHA particle manufacturing, and its modification was managed as a manufacturing change.
S178 concerns a different control chain. An unchanged sample does not guarantee identical results after a microscope is replaced. Calibration, resolution, magnification, image-analysis settings, and boundary detection can all affect particle-size data. The purpose of equipment qualification is not simply to show that the new microscope can image particles, but to establish that it produces reliable and comparable results under the specified method. For particle materials, the measurement system is part of the quality evidence.
Mature Products Still Have Manufacturing Lifecycles
The original U.S. PMA for RADIESSE was approved in 2006. Later public records describe an alternate processing pathway for CaHA particle byproducts in 2021, a new in-process test and a new sieve system in 2023, and updated quality-control equipment in 2024. The 2026 records continue that sequence with changes involving sieving, drying, filtration, and post-sterilization particle-size testing.
These records are not a complete change history, and they do not show that every change improved performance. They demonstrate that approval does not freeze manufacturing. Equipment, capacity, and test systems may evolve, provided that the effect of each relevant change is assessed and the necessary validation, documentation, and regulatory communication are completed.
A COA Does Not Replace Process Evidence
A certificate of analysis can show whether a released batch met specified test requirements. It cannot, by itself, establish that the manufacturing process remained stable or that measurements stayed comparable across an equipment change. Quality evidence for medical-use CaHA spans several levels:
| Control level | Typical evidence | Primary question |
|---|---|---|
| Material specification | Phase, Ca/P ratio, particle-size distribution, impurities | Does the batch meet its predefined requirements? |
| Manufacturing process | Key process parameters, equipment status, in-process tests | Did the process remain within its established control range? |
| Measurement system | Calibration, qualification, method suitability, equipment comparison | Are the results reliable and comparable? |
| Batch release | Final testing, deviation handling, release records | Can this batch proceed to the next stage? |
| Change control | Impact assessment, validation, documentation, required notification | Could the change alter the established quality state? |
This is why adding more tests does not automatically create a mature quality system. The stronger evidence is a stable relationship between process conditions and test results that can reveal drift, support batch comparison, and inform change assessment.
What This Means for Upstream CaHA Suppliers
An upstream materials supplier does not replicate the finished device's PMA system. It should, however, provide enough information for customers to identify the material, trace the batch, and assess change. As a project moves toward registration and scale-up, customer questions extend beyond particle size, Ca/P ratio, and XRD. They include distribution comparability after equipment changes, bridging between old and new test systems, and notification of relevant raw-material, equipment, or process changes.
A practical supplier package therefore has three parts: clear material specifications, batch and trend data that indicate process consistency, and a defined change-notification framework. Powder, formed microspheres, and complete formulations also remain different material levels; the data from one cannot substitute for another. See our overview of CaHA powder, microspheres, and injectable formulations for that distinction.
The Goal Is Controlled Change, Not No Change
Manufacturing equipment and test systems will not remain unchanged indefinitely. The practical objective is to bring each relevant change into a defined assessment: identify the affected quality attributes, determine the necessary comparison data, confirm whether specifications remain appropriate, and document and communicate the outcome.
For CaHA particles, correct phase, composition, and particle size are the material foundation. Long-term consistency also depends on sieving, drying, filtration, measurement systems, and change control. Reliable quality requires final confirmation through testing and continued control throughout manufacturing.
This article uses publicly available FDA PMA and supplement records to discuss general principles of CaHA particle manufacturing and quality control. The public pages do not contain complete process parameters, validation packages, or proprietary information. No inference is made here about specific process effects, product-performance improvements, or quality rankings among CaHA products.
References
- U.S. Food and Drug Administration. PMA P050052/S176: Green Sieve System for CaHA particle manufacturing. Decision date: March 24, 2026. FDA record.
- U.S. Food and Drug Administration. PMA P050052/S177: Conical dryer for CaHA particle manufacturing. Decision date: March 24, 2026. FDA record.
- U.S. Food and Drug Administration. PMA P050052/S178: New microscope for post-sterilization particle-size testing. Decision date: May 14, 2026. FDA record.
- U.S. Food and Drug Administration. PMA P050052/S179: Modification of the Dynamic Crossflow Filtration System. Decision date: June 26, 2026. FDA record.
- U.S. Food and Drug Administration. Original PMA P050052: RADIESSE Injectable Implant. Decision date: December 22, 2006. FDA record.
- U.S. Food and Drug Administration. PMA P050052/S128: Alternate processing pathway for CaHA particle byproducts. Decision date: August 27, 2021. FDA record.
- U.S. Food and Drug Administration. PMA P050052/S150: New in-process test for CaHA particle manufacturing. Decision date: July 12, 2023. FDA record.
- U.S. Food and Drug Administration. PMA P050052/S153: New sieve system for CaHA particle manufacturing. Decision date: September 20, 2023. FDA record.
- U.S. Food and Drug Administration. PMA P050052/S165: Updated quality-control test equipment for CaHA particles. Decision date: December 11, 2024. FDA record.
- U.S. Food and Drug Administration. 30-Day Notices, 135-Day Premarket Approval Supplements and 75-Day Humanitarian Device Exemption Supplements for Manufacturing Method or Process Changes. Guidance for Industry and FDA Staff. December 2019. FDA guidance.